CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

CAT

872.43

+1.39%↑

299.94

+5.33%↑

GEV.US

1,023.5

+1.19%↑

RTX

175.21

+0.4%↑

222.27

+3.4%↑

Home・Stock List・Ocugen Inc

Ocugen Inc

Closed

1.35 4.65

Buy Sell

Overview

Share price change

24h

Current

Min

1.3

Max

1.3599999999999999

Key metrics
By Trading Economics
Income	-1.5M -19M
Sales	1.7M 1.5M
EPS	-0.06
Profit margin	-1,250.946
Employees	116
EBITDA	-987K -17M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+790% upside

Dividends
By Dow Jones
Next Earnings	31 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-173M 454M
Previous open	-3.3
Previous close	1.35

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.6818 / 0.74 Support & Resistance

Ocugen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 May 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 May 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 May 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 May 2026, 23:28 UTC

Market Talk

Earnings

Global Forex and Fixed Income Roundup: Market Talk

19 May 2026, 23:28 UTC

Market Talk

Earnings

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 May 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19 May 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 May 2026, 22:02 UTC

Earnings

ZTO Express (Cayman): Di Xu to Resign From Board

19 May 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 May 2026, 22:01 UTC

Earnings

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 May 2026, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 May 2026, 21:37 UTC

Earnings

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 May 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 May 2026, 21:01 UTC

Earnings

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 May 2026, 20:58 UTC

Earnings

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 May 2026, 20:46 UTC

Hot Stocks

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 May 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 May 2026, 20:34 UTC

Earnings

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 May 2026, 20:32 UTC

Earnings

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 May 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q EPS 5c >JHX

19 May 2026, 20:32 UTC

Earnings

James Hardie Industries 4Q Sales $1.4B >JHX

19 May 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 May 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 May 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 May 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 May 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 May 2026, 20:03 UTC

Acquisitions, Mergers, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 May 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 May 2026, 20:02 UTC

Acquisitions, Mergers, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 May 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

790% upside

12 Months Forecast

Average 11.57 USD 790%

High 22 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Ocugen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.